KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Research & Development: 2017-2025

Historic Research & Development for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $63.4 million.

  • Amneal Pharmaceuticals' Research & Development rose 3.69% to $63.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.6 million, marking a year-over-year increase of 12.65%. This contributed to the annual value of $190.7 million for FY2024, which is 16.32% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Research & Development is $63.4 million, which was up 32.08% from $48.0 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Research & Development peaked at $63.4 million during Q3 2025, and registered a low of $36.1 million during Q2 2024.
  • In the last 3 years, Amneal Pharmaceuticals' Research & Development had a median value of $41.4 million in 2023 and averaged $46.0 million.
  • In the last 5 years, Amneal Pharmaceuticals' Research & Development fell by 26.72% in 2023 and then spiked by 47.67% in 2024.
  • Amneal Pharmaceuticals' Research & Development (Quarterly) stood at $51.9 million in 2021, then fell by 19.21% to $41.9 million in 2022, then grew by 9.97% to $46.1 million in 2023, then increased by 17.75% to $54.3 million in 2024, then climbed by 3.69% to $63.4 million in 2025.
  • Its Research & Development was $63.4 million in Q3 2025, compared to $48.0 million in Q2 2025 and $40.0 million in Q1 2025.